Literature DB >> 23276773

GeneXpert® for smear-negative pulmonary tuberculosis: does it play a role in low-burden countries?

Laura Muñoz1, Raquel Moure, Nuria Porta, Lucia Gonzalez, Rosario Guerra, Fernando Alcaide, Miguel Santin.   

Abstract

We performed a retrospective analysis of costs and time to treatment (TT) of 150 culture-confirmed TB cases: 100 sputum smear (SS) (+) and 50 SS(-). This group underwent GeneXpert® (GX) assay. Expenditures and TT of SS(-)/GX(+) cases were inferred from the SS(+) group. GX detected 68% of SS(-) cases.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23276773     DOI： 10.1016/j.diagmicrobio.2012.11.011

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  7 in total

1.  GeneXpert in the diagnosis of smear-negative PTB.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Afr Health Sci       Date:  2014-06       Impact factor: 0.927

Review 2.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

Review 3.  Evaluation of the Cepheid Xpert MTB/RIF assay.

Authors:  Thomas M Shinnick; Angela M Starks; Heather L Alexander; Kenneth G Castro
Journal:  Expert Rev Mol Diagn       Date:  2014-11-06       Impact factor: 5.225

4.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

Review 5.  Tuberculosis in patients with haematological malignancies.

Authors:  Luis Anibarro; Alberto Pena
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-04-07       Impact factor: 2.576

6.  Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia.

Authors:  Helen R Stagg; Peter J White; Vija Riekstiņa; Andra Cīrule; Ģirts Šķenders; Vaira Leimane; Liga Kuksa; Gunta Dravniece; James Brown; Charlotte Jackson
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

7.  Diagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIF.

Authors:  Giulia Lombardi; Valentina Di Gregori; Nicolò Girometti; Marina Tadolini; Francesco Bisognin; Paola Dal Monte
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.